Century Therapeutics

Century uses induced pluripotent stem cells (iPSCs) as a starting material to manufacture allogeneic NK and T cell therapies. The platform relies on a single clonal master cell bank that is gene-edited with multiple transgenes for enhanced persistence, tumor targeting, and allo-evasion. This approach aims to produce an off-the-shelf product that avoids the patient-specific manufacturing required by autologous CAR-T therapies.

Century's research and development is distributed across sites in Philadelphia, Boston, and Branchburg, New Jersey. The Philadelphia location serves as the primary headquarters, while Branchburg anchors process development and manufacturing operations. An additional operational node exists in Leverkusen, Germany.

No. Century Therapeutics is a publicly traded biotechnology company. Its operational structure, governance, and financial disclosures follow SEC reporting standards. It is not structured as a family office or investment management vehicle and does not manage third-party capital in the sense of a fund.

Traditional CAR-T therapies are autologous, meaning a patient's own T cells are harvested, engineered, and reinfused. Century's allogeneic candidates are differentiated from a single iPSC line, so they are not patient-specific. This 'off-the-shelf' model is designed to enable repeat dosing, reduce manufacturing timelines, and potentially lower the cost of goods versus first-generation cell therapies.

The company's lead disclosed program is CNTY-101, an allogeneic, iPSC-derived NK cell therapy targeting CD19. The candidate incorporates multiple gene edits, including a CD19-targeting CAR, IL-15 pathway support, and allo-evasion strategies designed to prevent host rejection. It is being evaluated for relapsed or refractory B-cell malignancies.